Navigation Links
Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
Date:2/1/2010

RICHMOND, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 9:00 am ET on Monday, February 8, 2010 at the 12th Annual BIO CEO & Investor Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neu
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
2. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
3. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
4. Sangamo Announces Pricing of Public Offering of Common Stock
5. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
6. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
7. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
8. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
9. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
10. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
11. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... VetStem Biopharma ... Equine cervical facet joint problems can be caused by injuries and abnormalities of ... of nerve roots or of the spinal cord itself. This can manifest itself ...
(Date:9/1/2015)... ... 2015 , ... Knowledgent , the data and analytics firm, today announced ... data lakes in the healthcare industry. , As the Internet of Things (IoT) continues ... the last few years as more entities become technology enabled through Electronic Medical Records ...
(Date:9/1/2015)... ... ... A new host-based therapy for Ebola, anthrax and other ... and its collaborators. The discovery has the potential to speed to market treatments ... by Scientific Reports, an open access research journal from the publishers of Nature. ...
(Date:9/1/2015)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... of Directors as a Non-Executive Director. Sara will also be ... the Shire Board. Both appointments will be effective as of ... President and Chief Executive Officer of Dun & Bradstreet, Inc. ... D&B, she helped drive the transformation of the company from ...
Breaking Biology Technology:VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Shire Appoints Sara Mathew to Board of Directors 2
... Health Care Compliance Strategies, Inc. (HCCS) , ... training, today announced the release of a new online ... Associates (BAs) . Responding to expanded HIPAA Privacy Rule ... an online course designed to assist healthcare vendors in ...
... , a venture backed clinical stage biotechnology company developing ... from the Phase 2b trial of ARC-4558 for the ... will be the subject of two poster presentations at ... at the American Diabetes Association,s 71st Scientific Sessions, June ...
... Reportlinker.com announces that a new market research ... Global Immunochemicals Industry ... report analyzes the worldwide markets for Immunochemicals ... segments – Catalog Antibodies, and Custom Antibodies. ...
Cached Biology Technology:New Online Training Course Helps Healthcare Vendors Comply with HIPAA Regulations 2New Online Training Course Helps Healthcare Vendors Comply with HIPAA Regulations 3Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 2Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 3Reportlinker Adds Global Immunochemicals Industry 2Reportlinker Adds Global Immunochemicals Industry 3Reportlinker Adds Global Immunochemicals Industry 4Reportlinker Adds Global Immunochemicals Industry 5Reportlinker Adds Global Immunochemicals Industry 6Reportlinker Adds Global Immunochemicals Industry 7Reportlinker Adds Global Immunochemicals Industry 8Reportlinker Adds Global Immunochemicals Industry 9Reportlinker Adds Global Immunochemicals Industry 10
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Saudi Arabia Biomedical Sensors Market - ... offering. The Saudi Arabia Biomedical Sensors ... a CAGR of 3.64% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:8/24/2015)... The consulting company Frost & Sullivan ... DERMALOG and its customized solutions and products for ... the Year Award". DERMALOG is particularly successful with a large ... -Cross reference: Picture is available at AP Images ( ... Thursday evening, in South Africa,s economic ...
(Date:8/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... Smart Card Alliance and the EMV Migration Forum.  ... Smart Card Alliance Latin America (SCALA) Chapter provides NXT-ID, ... thought leaders promoting adoption of smart card technology. ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... (self-donated) mononuclear cells derived from bone marrow (BMMNCs) have ... into patients with diabetes who are suffering from critical ... complication of diabetes. The team of researchers in Seville, ... in a recent issue of Cell Transplantation ...
... of Alberta is working with scientists from across North America to ... 15 scientists will examine DNA samples from children with autism and ... risk. , , And if siblings are at high risk ... , If theres a family of a child with autism, they ...
... Boston In a breakthrough for the way brain cancer ... Anna M. Krichevsky, PhD, of the Center of Neurologic Diseases ... Kesari, MD, PhD, director of Neuro-Oncology at UC San Diego ... reliably diagnosed and monitored without surgery. Previously, an accurate ...
Cached Biology News:Autologous bone marrow-derived mononuclear cell transplants can reduce diabetic amputations 2Researchers across North America team up to find genetic markers for autism 2
... This product is expected to ... mammalian species but has not been ... single precipitin line against partially purified ... to react with all forms of ...
... of the COP9 signalosome complex (CSN), a ... processes. The CSN complex is an essential ... by mediating the deneddylation of the cullin ... complex is also involved in phosphorylation of ...
... • Enzyme concentration - 5 units/µL ... in higher yields ,• Leaves an 'A' ... DNA polymerase which exhibits very high activity ... applications. To ensure the quality of the ...
... units/µL ,• High specific activity and processivity ... 'A' overhang ,• Processes ... high activity in primer extension and other ... of the enzyme, each lot has been ...
Biology Products: